Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteine dioxygenase type 1 (CDO1)
- Target
- CDO1
- Molecular classification
- Enzyme, Iron-containing metalloenzyme, Non-heme Fe(II) dioxygenase
01
Overview
Cysteine dioxygenase type 1 (CDO1) is a non-heme, iron-dependent enzyme that catalyzes the first and rate-limiting step of cysteine catabolism, converting cysteine to cysteine sulfinic acid—a precursor in taurine and sulfate metabolism. CDO1 is tightly regulated and essential for controlling intracellular cysteine levels and redox balance. Dysregulation or epigenetic silencing of CDO1 is frequently observed in multiple cancers, correlating with tumor progression, poor prognosis, and altered chemotherapeutic response. Beyond cancer, CDO1 is implicated in lipid metabolism, redox homeostasis, neurodegenerative diseases, and other metabolic and developmental processes. CDO1 is thus a biologically significant enzyme and a promising diagnostic and prognostic biomarker, though not yet a direct drug target in clinical therapeutics
- Other names
- CDOCDO-ICysteine dioxygenase type Icysteine dioxygenase, type ICDO1
02
Mechanism of action
Enzyme inhibition (potential mechanism for experimental compounds; currently not clinically targeted) Epigenetic modulation (biomodulators, e.g., demethylating agents, could restore CDO1 expression in cancer models, but these are not specific drugs for CDO1)
03
Biological functions
Cysteine catabolismRegulation of intracellular cysteine levelsRedox homeostasisTaurine biosynthesisLipid metabolismAdipogenesisOsteoblastic differentiationBile acid metabolismSulfide metabolismRegulation of cellular metabolism and ROS (reactive oxygen species) balanceControl of organismal growth and development
04
Disease associations
Cancer (e.g., tumor suppressor role, epigenetically silenced in various cancers)Metabolic disordersNeurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, motor neuron disease)Rheumatoid arthritis
05
Safety considerations
Risk of altered cysteine and redox balance with inhibition/modulationPotential impact on systemic taurine, sulfate, and lipid metabolism, which could affect multiple organs
06
Biomarkers
CDO1 promoter methylation (cancer biomarker for colorectal, breast, lung, esophageal, bladder, and stomach cancer)CDO1 gene expression (tumor progression and prognosis, responsiveness to therapy)
Beyond the preview
Go deeper on Cysteine dioxygenase type 1 (CDO1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cysteine dioxygenase type 1 (CDO1).